Amylyx Pharmaceuticals, Inc.

NASDAQ:AMLX

Biotechnology

Healthcare
$26.62 +0.93%

+$0.14 today

Market cap
$3.42B
Beta
-0.16
P/E (TTM)
-11.3
EPS (TTM)
-$1.36
52W Low $4.80High $18.61

Volume 1.51M

Average 1.21M

AMLX Net Receivables

Amounts owed to the company by customers and others, net of allowances for uncollectible accounts.

Amylyx Pharmaceuticals, Inc.NASDAQ: AMLX

Net Receivables · Q3 FY2026 · quarter ended Sep 2026

Net receivables rises 1150.0% from a year ago

Net receivables stood at $2.9M at the end of Q3 FY2026, up 1150.0% from a year earlier. Over 3 fiscal years it compounded at -82.1% a year.

Context

  • Net receivables amounted to 0.4% of total assets at the end of Q3 FY2026, up 0.3 pp from a year earlier.
  • Net receivables increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether net receivables keeps rising in the next quarterly balance sheet after a +1150.0% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterSep 2026
$2.9M— QoQ
Last fiscal yearDec 2025
$88K-80.3% YoY
Year agoSep 2025
$232K+1150.0% since
Net Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+1150.0%——
1 year-80.3%——
3-year CAGR-82.1%——
5-year CAGR——
10-year CAGR——

Net Receivables history

USD · from the balance sheet

Latest · FY2025
88K USD
Year-over-year change
-80.3%

Net Receivables vs competitors

How AMLX compares with its peers on the latest reported figures

  • Peers report in different currencies, so net receivables is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of +1150.0% is the highest of 7, against a peer median of +20.0%.
  • Net receivables amounts to 0.4% of total assets for AMLX, versus a peer median of 0.4%.
AMLX Competitors
Net Receivables for AMLX and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
IONSIonis Pharmaceuticals, Inc.Sep 2026$88.34M USD+253.4%+37.2%3.0%
DNLIDenali Therapeutics Inc.Jun 2026$3.93M USD—-38.3%0.3%
CLNNClene Inc.Mar 2026$3.51M USD+132.4%-41.6%16.2%
AMLXAmylyx Pharmaceuticals, Inc.Sep 2026$2.9M USD+1150.0%-82.1%0.4%
ACIUAC Immune S.A.Mar 2026CHF 1.51M CHF+63.5%+18.7%1.1%
AVXLAnavex Life Sciences Corp.Dec 2025$844K USD-67.0%-36.7%0.6%
ELDNEledon Pharmaceuticals, Inc.Mar 2026$583K USD-23.4%—0.4%
PRAXPraxis Precision Medicines, Inc.Sep 2026$0 USD——0.0%
PRTAProthena Corporation plcMar 2026$0 USD——0.0%
PMNProMIS Neurosciences, Inc.Jun 2026$0 USD-100.0%—0.0%
Peer median (excluding AMLX) —+20.0%-36.7%0.4%

Competitors are the stored peer set for AMLX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents50.19M62.53M170.2M77.39M226.65M
Short-term Investments45.93M284.42M201.16M99.11M90.33M
Net Receivables015.31M40.05M447K88K
Inventory09.77M38.32M00
Other Current Assets3.44M10.11M14.93M12.48M6.6M
Total Current Assets104.95M382.13M464.67M189.43M323.67M
Property, Plant & Equipment (Net)474K8.14M6.41M2.73M5.49M
Goodwill00000
Intangible Assets00000
Long-term Investments00000
Tax Assets00000
Other Non-current Assets189K1.19M46.38M1.47M3.48M
Total Non-current Assets663K9.32M52.79M4.2M8.97M
Total Assets105.61M391.45M517.45M193.63M332.65M
Account Payables4.37M6.26M22.06M2.94M3.52M
Short-term Debt00000
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities4.28M15.23M40.93M9.99M10.06M
Total Current Liabilities17.4M46.61M82.04M28.41M22.69M
Long-term Debt00004.7M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities239.39M0000
Total Non-current Liabilities239.39M4.24M1.98M463K4.7M
Total Liabilities256.78M50.85M84.02M28.87M27.39M
Common Stock1K7K7K7K11K
Retained Earnings(155.85M)(354.22M)(304.95M)(606.69M)(751.43M)
Accumulated OCI9K(86K)197K(92K)404K
Other Stockholders Equity00000
Minority Interest00000
Total Equity(151.17M)340.61M433.43M164.77M305.26M
Total Debt06.28M4.24M1.98M5.96M
Net Debt(50.19M)(56.25M)(165.96M)(75.41M)(220.69M)

Amylyx Pharmaceuticals, Inc.

NASDAQ:AMLX

Intrinsic Alpha fair value

Locked

Current Price

$26.62

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.